Figure S2 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
Year: 2026
Type: other
Abstract: Biochemical, biophysical, structural and cellular characterization of KB528 pharmacology.
Authors: W. Frank Lenoir, Michael R. McKeown, Giulia Giorgetti, Marek J. Kobylarz, Tamara D. Hopkins, Wayne L. Glore, Michelle G. Shum, Yaretzi Calderón, Jessica Encinas Mayoral, Luis A. Carvajal, Kameron R. Mori, Jun Li, Hua Gao, Yupeng Zheng, Zhihua Ma, Nikolaus D. Obholzer, Minyun Zhou, Benjamin W. Trotter, Christopher J. Dinsmore, Nikhil C. Munshi, Charles Y. Lin, Mariateresa Fulciniti, Peter B. Rahl
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7129093935